Spontaneous bacterial peritonitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(25 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Spontaneous bacterial peritonitis}}
{{Spontaneous bacterial peritonitis}}
{{CMG}}; {{AE}} {{ADI}}, {{chetan}}, {{GRN}}, {{AL}} {{SCh}}
{{CMG}}; {{AE}} {{ADI}}, {{chetan}}, {{GRN}}, {{AL}} {{SCh}}{{AY}}


==Overview==
==Overview==


Empiric broad-spectrum [[intravenous]] [[antibiotic]], preferably with a third generation [[cephalosporin]] such as [[cefotaxime]], is warranted for suspected or established [[spontaneous bacterial peritonitis|spontaneous bacterial peritonitis (SBP)]] to cover the most common isolates including ''[[Escherichia coli]]'', ''[[Klebsiella pneumoniae]]'', and ''[[Streptococcus pneumoniae]]''. Oral [[ofloxacin]] may be considered in selected cases. [[Albumin]] infusion should be reserved for patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> and clinical suspicion of SBP, who also have a serum [[creatinine]] &gt;1 mg/dL, [[blood urea nitrogen]] &gt;30 mg/dL, or total [[bilirubin]] &gt;4 mg/dL. The use of non-selective [[beta blockers]] in [[cirrhosis|cirrhotic]] patients with SBP should be discouraged since it is associated with an increased risk for [[hemodynamic compromise]], prolonged [[hospitalization]], [[hepatorenal syndrome]], and [[acute kidney injury]].
Empiric broad-spectrum [[intravenous]] [[antibiotic]], preferably a third generation [[cephalosporin]] such as [[cefotaxime]], is warranted for suspected or established [[spontaneous bacterial peritonitis|spontaneous bacterial peritonitis (SBP)]] to cover the most common isolates including ''[[Escherichia coli]]'', ''[[Klebsiella pneumoniae]]'', and ''[[Streptococcus pneumoniae]]''.<ref name="pmid11786457">{{cite journal| author=Soares-Weiser K, Paul M, Brezis M, Leibovici L| title=Evidence based case report. Antibiotic treatment for spontaneous bacterial peritonitis. | journal=BMJ | year= 2002 | volume= 324 | issue= 7329 | pages= 100-2 | pmid=11786457 | doi= | pmc=1121993 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11786457  }} </ref> Oral [[ofloxacin]] may be considered in selected cases. [[Albumin]] infusion should be reserved for patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> and clinical suspicion of SBP, who also have a serum [[creatinine]] >1 mg/dL, [[blood urea nitrogen]] >30 mg/dL, or total [[bilirubin]] >4 mg/dL. The use of non-selective [[beta blockers]] in [[cirrhosis|cirrhotic]] patients with SBP should be discouraged since it is associated with an increased risk for [[hemodynamic compromise]], prolonged [[hospitalization]], [[hepatorenal syndrome]], and [[acute kidney injury]].<ref name="pmid24631577">{{cite journal| author=Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M et al.| title=Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. | journal=Gastroenterology | year= 2014 | volume= 146 | issue= 7 | pages= 1680-90.e1 | pmid=24631577 | doi=10.1053/j.gastro.2014.03.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24631577  }} </ref>


==Medical Therapy <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''AASLD Practice Guidelines: Management of Adult Patients with Ascites Due to Cirrhosis''.<ref name=AASLD2013>{{cite web
==Medical Therapy <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''AASLD Practice Guidelines: Management of Adult Patients with Ascites Due to Cirrhosis''.<ref name=AASLD2013>{{cite web
Line 20: Line 20:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q8h (or 2 g IV q4h if life-threatening) x 5–10 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q8h (or 2 g IV q4h if life-threatening) x 5–10 days<ref name="pmid11871762">{{cite journal| author=França A, Giordano HM, Sevá-Pereira T, Soares EC| title=Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. | journal=J Gastroenterol | year= 2002 | volume= 37 | issue= 2 | pages= 119-22 | pmid=11871762 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11871762  }} </ref>'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Ofloxacin]] 400 mg PO bid x 5–10 days'''''<sup>†</sup><BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 200 mg IV q12h x 7 days'''''<sup>†</sup><BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 200 mg IV q12h x 2 days, then 500 mg PO bid x 5 days'''''<sup>†</sup>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Ofloxacin]] 400 mg PO bid x 5–10 days'''''<sup>†</sup><BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 200 mg IV q12h x 7 days'''''<sup>†</sup><BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 200 mg IV q12h x 2 days, then 500 mg PO bid x 5 days'''''<sup>†</sup><ref name="pmid11059861">{{cite journal| author=Terg R, Cobas S, Fassio E, Landeira G, Ríos B, Vasen W et al.| title=Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. | journal=J Hepatol | year= 2000 | volume= 33 | issue= 4 | pages= 564-9 | pmid=11059861 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11059861  }} </ref>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <sup>†</sup> <SMALL>Should <u>not</u> be used in a patient who had been receiving a quinolone for prophylaxis.</SMALL><ref name="pmid8831596">{{cite journal| author=Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A et al.| title=Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. | journal=Gastroenterology | year= 1996 | volume= 111 | issue= 4 | pages= 1011-7 | pmid=8831596 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8831596  }} </ref><ref name="pmid11059861">{{cite journal| author=Terg R, Cobas S, Fassio E, Landeira G, Ríos B, Vasen W et al.| title=Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. | journal=J Hepatol | year= 2000 | volume= 33 | issue= 4 | pages= 564-9 | pmid=11059861 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11059861  }} </ref>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <sup>†</sup> <SMALL>Should <u>not</u> be used in a patient who had been receiving a quinolone for prophylaxis.</SMALL><ref name="pmid8831596">{{cite journal| author=Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A et al.| title=Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. | journal=Gastroenterology | year= 1996 | volume= 111 | issue= 4 | pages= 1011-7 | pmid=8831596 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8831596  }} </ref><ref name="pmid11059861">{{cite journal| author=Terg R, Cobas S, Fassio E, Landeira G, Ríos B, Vasen W et al.| title=Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. | journal=J Hepatol | year= 2000 | volume= 33 | issue= 4 | pages= 564-9 | pmid=11059861 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11059861  }} </ref>
Line 41: Line 41:
|}
|}


* Empiric antibiotic therapy should be administered to patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> in a clinical setting compatible with [[ascites|ascitic fluid]] [[infection]] or those who have convincing signs or symptoms of infection ([[fever]], [[abdominal pain]], or unexplained [[encephalopathy]]) regardless of the [[PMN]] count in the [[ascites|ascitic fluid]].<ref>{{Cite journal
* Empiric [[antibiotic therapy]] should be administered to patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> in a clinical setting compatible with [[ascites|ascitic fluid]] [[infection]] or those who have convincing signs or symptoms of infection ([[fever]], [[abdominal pain]], or unexplained [[encephalopathy]]) regardless of the [[PMN]] count in the [[ascites|ascitic fluid]].<ref name="pmid23463403">{{cite journal| author=Runyon BA, AASLD| title=Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. | journal=Hepatology | year= 2013 | volume= 57 | issue= 4 | pages= 1651-3 | pmid=23463403 | doi=10.1002/hep.26359 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23463403  }} </ref><ref name="pmid7095741">{{cite journal| author=Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ| title=Spontaneous bacterial peritonitis. | journal=Hepatology | year= 1982 | volume= 2 | issue= 4 | pages= 399-407 | pmid=7095741 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7095741  }} </ref>
| doi = 10.1002/hep.26359
| issn = 1527-3350
| volume = 57
| issue = 4
| pages = 1651–1653
| last = Runyon
| first = Bruce A
| coauthors = AASLD
| title = Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012
| journal = Hepatology (Baltimore, Md.)
| date = 2013-04
| pmid = 23463403
}}</ref><ref>{{Cite journal
| issn = 0270-9139
| volume = 2
| issue = 4
| pages = 399–407
| last = Hoefs
| first = J C
| coauthors = H N Canawati, F L Sapico, R R Hopkins, J Weiner, J Z Montgomerie
| title = Spontaneous bacterial peritonitis
| journal = Hepatology (Baltimore, Md.)
| date = 1982-08
| pmid = 7095741
}}</ref>


* Bacterascites is defined as an [[ascites|ascitic]] [[neutrophil]] count less than 250/mm<sup>3</sup> but with a positive [[ascites|ascitic fluid]] culture. If the patient exhibits signs of systemic [[inflammation]] or [[infection]], the patient should be treated with [[antibiotics]]. Otherwise, the patient should undergo a second [[paracentesis]] when culture results turns positive. Patients in whom the repeat [[ascites|ascitic]] [[neutrophil]] count is >250/mm<sup>3</sup> should be treated for SBP, and the remaining patients (i.e., [[neutrophil]]s <250/mm<sup>3</sup>) should be followed up.<ref>{{Cite journal
* Bacterascites is defined as an [[ascites|ascitic]] [[neutrophil]] count less than 250/mm<sup>3</sup> but with a positive [[ascites|ascitic fluid]] culture. If the patient exhibits signs of systemic [[inflammation]] or [[infection]], the patient should be treated with [[antibiotics]]. Otherwise, the patient should undergo a second [[paracentesis]] when [[Culture medium|culture]] results turns positive. Patients in whom the repeat [[ascites|ascitic]] [[neutrophil]] count is >250/mm<sup>3</sup> should be treated for SBP, and the remaining patients (i.e., [[neutrophil]]s <250/mm<sup>3</sup>) should be followed up.<ref name="pmid20633946">{{cite journal| author=European Association for the Study of the Liver| title=EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. | journal=J Hepatol | year= 2010 | volume= 53 | issue= 3 | pages= 397-417 | pmid=20633946 | doi=10.1016/j.jhep.2010.05.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20633946  }} </ref>
| doi = 10.1016/j.jhep.2010.05.004
| issn = 1600-0641
| volume = 53
| issue = 3
| pages = 397–417
| last = European Association for the Study of the Liver
| title = EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
| journal = Journal of hepatology
| date = 2010-09
| pmid = 20633946
}}</ref>


* The most common isolates from the [[ascites|ascitic fluid]] are ''[[Escherichia coli]]'', ''[[Klebsiella pneumoniae]]'', and ''[[Streptococcus pneumoniae]]''.
* The most common isolates from the [[ascites|ascitic fluid]] are ''[[Escherichia coli]]'', ''[[Klebsiella pneumoniae]]'', and ''[[Streptococcus pneumoniae]]''.


* Relatively broad-spectrum therapy, preferably with [[cefotaxime]], is warranted until the results of susceptibility testing are available.
* Relatively [[Broad-spectrum antibiotic|broad-spectrum]] therapy, preferably with [[cefotaxime]], is warranted until the results of susceptibility testing are available.


* Infection with [[MDR|multiresistant]] organism including [[ESBL|Extended-spectrum β-lactamase (ESBL)]]-producing ''[[Enterobacteriaceae]]'', ''[[Pseudomonas aeruginosa]]'', [[MRSA|methicillin-resistant ''Staphylococcus aureus'' (MRSA)]], and ''[[Enterococcus faecium]]'' is associated with an increased [[mortality]]. [[Risk factor]]s for [[MDR|multiresistant]] infections include:<ref>{{Cite journal
* Infection with [[MDR|multiresistant]] organism including [[ESBL|Extended-spectrum β-lactamase (ESBL)]]-producing ''[[Enterobacteriaceae]]'', ''[[Pseudomonas aeruginosa]]'', [[MRSA|methicillin-resistant ''Staphylococcus aureus'' (MRSA)]], and ''[[Enterococcus faecium]]'' is associated with an increased [[mortality]]. [[Risk factor]]s for [[MDR|multiresistant]] infections include:<ref name="pmid22183941">{{cite journal| author=Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D et al.| title=Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. | journal=Hepatology | year= 2012 | volume= 55 | issue= 5 | pages= 1551-61 | pmid=22183941 | doi=10.1002/hep.25532 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22183941  }} </ref><ref name="pmid23463403">{{cite journal| author=Runyon BA, AASLD| title=Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. | journal=Hepatology | year= 2013 | volume= 57 | issue= 4 | pages= 1651-3 | pmid=23463403 | doi=10.1002/hep.26359 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23463403  }} </ref>
| doi = 10.1002/hep.25532
| issn = 1527-3350
| volume = 55
| issue = 5
| pages = 1551–1561
| last = Fernández
| first = Javier
| coauthors = Juan Acevedo, Miriam Castro, Orlando Garcia, Carlos Rodríguez de Lope, Daria Roca, Marco Pavesi, Elsa Sola, Leticia Moreira, Anibal Silva, Tiago Seva-Pereira, Francesco Corradi, Jose Mensa, Pere Ginès, Vicente Arroyo
| title = Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study
| journal = Hepatology (Baltimore, Md.)
| date = 2012-05
| pmid = 22183941
}}</ref>
:* [[Nosocomial]] origin of infection
:* [[Nosocomial]] origin of infection
:* Long-term [[norfloxacin]] prophylaxis
:* Long-term [[norfloxacin]] prophylaxis
Line 118: Line 69:
}}</ref>
}}</ref>


* The optimal duration of therapy remains unclear, although most patients respond to a treatment course of five days. Infection-related [[mortality]], bacteriologic cure, and recurrence of [[ascites|ascitic fluid]] infection were not significantly different between the 5- and 10-day treatment groups in a randomized trial.<ref>{{Cite journal
* The optimal duration of therapy remains unclear, although most patients respond to a treatment course of five days. Infection-related [[mortality]], bacteriologic cure, and recurrence of [[ascites|ascitic fluid]] infection were not significantly different between the 5- and 10-day treatment groups in a randomized trial.<ref name="pmid2019378">{{cite journal| author=Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA| title=Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. | journal=Gastroenterology | year= 1991 | volume= 100 | issue= 6 | pages= 1737-42 | pmid=2019378 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2019378  }} </ref>
| issn = 0016-5085
| volume = 100
| issue = 6
| pages = 1737–1742
| last = Runyon
| first = B A
| coauthors = J G McHutchison, M R Antillon, E A Akriviadis, A A Montano
| title = Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients
| journal = Gastroenterology
| date = 1991-06
| pmid = 2019378
}}</ref>
 
* [[Albumin]] infusion should be administered to [[cirrhosis|cirrhotic]] patients with [[spontaneous bacterial peritonitis]] in the following conditions:<ref>{{Cite journal
| doi = 10.1136/gut.2006.113050
| issn = 0017-5749
| volume = 56
| issue = 4
| pages = 597–599
| last = Sigal
| first = Samuel H
| coauthors = Carmen M Stanca, Javier Fernandez, Vicente Arroyo, Miguel Navasa
| title = Restricted use of albumin for spontaneous bacterial peritonitis
| journal = Gut
| date = 2007-04
| pmid = 17369392
| pmc = PMC1856861
}}</ref>
:* Serum [[creatinine]] &gt;1 mg/dL
:* [[Blood urea nitrogen]] &gt;30 mg/dL
:* Total [[bilirubin]] &gt;4 mg/dL


* Adjunctive [[intravenous]] [[albumin]] at a dose of 1.5 g/kg at the time of diagnosis, followed by 1 g/kg on day 3 is associated with a reduced incidence of [[renal impairment]] and [[death]] in comparison with treatment with an [[antibiotic]] alone.<ref>{{Cite journal
===Adjunctive IV Albumin===
| doi = 10.1056/NEJM199908053410603
* In a randomized controlled study involving cirrhotic patients with SBP, the use of [[Albumin|IV albumin]] (1.5 g/kg given within 6 hours of enrollment and repeated as a 1.0 g/kg dose on day 3) as an adjunctive to [[cefotaxime]] was shown to decrease [[Mortality rate|in-hospital mortality]] when compared with use of [[cefotaxime]] alone (29% versus 10%). <ref name="pmid10432325">{{cite journal| author=Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al.| title=Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. | journal=N Engl J Med | year= 1999 | volume= 341 | issue= 6 | pages= 403-9 | pmid=10432325 | doi=10.1056/NEJM199908053410603 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10432325  }} </ref>
| issn = 0028-4793
| volume = 341
| issue = 6
| pages = 403–409
| last = Sort
| first = P
| coauthors = M Navasa, V Arroyo, X Aldeguer, R Planas, L Ruiz-del-Arbol, L Castells, V Vargas, G Soriano, M Guevara, P Ginès, J Rodés
| title = Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
| journal = The New England journal of medicine
| date = 1999-08-05
| pmid = 10432325
}}</ref>


* The use of non-selective [[beta blockers]] in [[cirrhosis|cirrhotic]] patients with SBP should be discouraged since it is associated with an increased risk for [[hemodynamic compromise]], prolonged [[hospitalization]], [[hepatorenal syndrome]], and [[acute kidney injury]].<ref>{{Cite journal
* In addition, those treated with [[albumin]] had a reduction in the development of [[renal impairment]] (10% versus 33%).
| doi = 10.1053/j.gastro.2014.03.005
* Use of [[Albumin|IV albumin]] should be reserved for patients with a:
| issn = 1528-0012
** Serum [[creatinine]] greater than 1 mg/dL,
| volume = 146
** [[Blood urea nitrogen]] greater than 30 mg/dL, or
| issue = 7
** Total [[bilirubin]] greater than 4 mg/dL.<ref name="pmid17369392">{{cite journal| author=Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M| title=Restricted use of albumin for spontaneous bacterial peritonitis. | journal=Gut | year= 2007 | volume= 56 | issue= 4 | pages= 597-9 | pmid=17369392 | doi=10.1136/gut.2006.113050 | pmc=1856861 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17369392  }} </ref>
| pages = 1680–1690.e1
| last = Mandorfer
| first = Mattias
| coauthors = Simona Bota, Philipp Schwabl, Theresa Bucsics, Nikolaus Pfisterer, Matthias Kruzik, Michael Hagmann, Alexander Blacky, Arnulf Ferlitsch, Wolfgang Sieghart, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger
| title = Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis
| journal = Gastroenterology
| date = 2014-06
| pmid = 24631577
}}</ref>


==Recommendations for the Management of Spontaneous Bacterial Peritonitis (2013 AASLD Practice Guideline)==
==Recommendations for the Management of Spontaneous Bacterial Peritonitis (2013 AASLD Practice Guideline)==
Line 193: Line 92:
# Patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> and clinical suspicion of SBP, who also have a serum [[creatinine]] >1 mg/dL, [[blood urea nitrogen]] >30 mg/dL, or total [[bilirubin]] >4 mg/dL should receive 1.5 g [[albumin]] per kg body weight within 6 hours of detection and 1.0 g/kg on day 3.
# Patients with [[ascites|ascitic fluid]] [[PMN]] counts greater than or equal to 250 cells/mm<sup>3</sup> and clinical suspicion of SBP, who also have a serum [[creatinine]] >1 mg/dL, [[blood urea nitrogen]] >30 mg/dL, or total [[bilirubin]] >4 mg/dL should receive 1.5 g [[albumin]] per kg body weight within 6 hours of detection and 1.0 g/kg on day 3.
}}
}}
===Followup Diagnostic Paracentesis===
* Follow-up ascitic fluid analysis is usually not necessary following treatment of SBP unless there is no clinical improvement in the patient’s symptoms, abnormal fluid analysis, suspected infection with multi-drug resistant organisms, or altered clinical course is noted.
* If the ascitic fluid [[PMNs|PMN]] count has not declined by at least 25% after two days of [[antibiotic therapy]], then the [[Antibiotic|antibiotic coverage]] needs to be broadened to cover resistant organisms and [[Secondary peritonitis|secondary bacterial peritonitis]] needs to be considered. 
* Patients with [[Secondary peritonitis|secondary bacterial peritonitis]] should undergo surgical intervention of the [[Bowel perforation|perforated viscus]] or drainage of the [[abscess]] and should be treated with [[Broad-spectrum antibiotic|broad-spectrum antibiotics]], such as [[Cephalosporins|third-generation cephalosporins]], with the addition of an [[antimicrobial agent]] that has good [[Anaerobic organism|anaerobic coverage]], such as [[metronidazole]]
** Consider repeat [[paracentesis]] after 48 hours of therapy
** Consider changing [[antibiotics]] if [[Ascites|ascitic fluid]] PMN has not dropped by 25% after 48 hours and/or patient is not responding clinically.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WS}}
{{WH}}


[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Emergency mdicine]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
{{WS}}
{{WH}}

Latest revision as of 00:15, 30 July 2020

Peritonitis main page

Spontaneous bacterial peritonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spontaneous bacterial peritonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Spontaneous bacterial peritonitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spontaneous bacterial peritonitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spontaneous bacterial peritonitis medical therapy

CDC on Spontaneous bacterial peritonitis medical therapy

Spontaneous bacterial peritonitis medical therapy in the news

Blogs on Spontaneous bacterial peritonitis medical therapy

Directions to Hospitals Treating Spontaneous bacterial peritonitis

Risk calculators and risk factors for Spontaneous bacterial peritonitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Chetan Lokhande, M.B.B.S [3], Guillermo Rodriguez Nava, M.D. [4], Alejandro Lemor, M.D. [5] Shivani Chaparala M.B.B.S [6]Ahmed Younes M.B.B.CH [7]

Overview

Empiric broad-spectrum intravenous antibiotic, preferably a third generation cephalosporin such as cefotaxime, is warranted for suspected or established spontaneous bacterial peritonitis (SBP) to cover the most common isolates including Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae.[1] Oral ofloxacin may be considered in selected cases. Albumin infusion should be reserved for patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 and clinical suspicion of SBP, who also have a serum creatinine >1 mg/dL, blood urea nitrogen >30 mg/dL, or total bilirubin >4 mg/dL. The use of non-selective beta blockers in cirrhotic patients with SBP should be discouraged since it is associated with an increased risk for hemodynamic compromise, prolonged hospitalization, hepatorenal syndrome, and acute kidney injury.[2]

Medical Therapy Adapted from AASLD Practice Guidelines: Management of Adult Patients with Ascites Due to Cirrhosis.[3]

Empiric Therapy
Preferred Regimen
Cefotaxime 2 g IV q8h (or 2 g IV q4h if life-threatening) x 5–10 days[4]
Alternative Regimen
Ofloxacin 400 mg PO bid x 5–10 days
OR
Ciprofloxacin 200 mg IV q12h x 7 days
OR
Ciprofloxacin 200 mg IV q12h x 2 days, then 500 mg PO bid x 5 days[5]
Should not be used in a patient who had been receiving a quinolone for prophylaxis.[6][5]
ESBL–producing Enterobacteriaceae
Preferred Regimen
Doripenem 500 mg IV q8h (1–hr infusion)
OR
Ertapenem 1 g IV q24h
OR
Imipenem–Cilastatin 0.5–1 g IV q6–8h
OR
Meropenem 1 g IV q8h
Alternative Regimen
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg IV q24h
Check in vitro susceptibility.[7][8]
  • Relatively broad-spectrum therapy, preferably with cefotaxime, is warranted until the results of susceptibility testing are available.
  • The optimal duration of therapy remains unclear, although most patients respond to a treatment course of five days. Infection-related mortality, bacteriologic cure, and recurrence of ascitic fluid infection were not significantly different between the 5- and 10-day treatment groups in a randomized trial.[14]

Adjunctive IV Albumin

  • In a randomized controlled study involving cirrhotic patients with SBP, the use of IV albumin (1.5 g/kg given within 6 hours of enrollment and repeated as a 1.0 g/kg dose on day 3) as an adjunctive to cefotaxime was shown to decrease in-hospital mortality when compared with use of cefotaxime alone (29% versus 10%). [15]

Recommendations for the Management of Spontaneous Bacterial Peritonitis (2013 AASLD Practice Guideline)

  1. Patients with ascites admitted to the hospital should undergo abdominal paracentesis. Paracentesis should be repeated in patients (whether in the hospital or not) who develop signs or symptoms or laboratory abnormalities suggestive of infection (e.g., abdominal pain or tenderness, fever, encephalopathy, renal failure, acidosis, or peripheral leukocytosis).
  2. Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 in a community-acquired setting in the absence of recent beta-lactam antibiotic exposure should receive empiric antibiotic therapy, e.g., an intravenous third-generation cephalosporin, preferably cefotaxime 2 g every 8 hours.
  3. Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 in a nosocomial setting and/or in the presence of recent beta-lactam antibiotic exposure should receive empiric antibiotic therapy based on local susceptibility testing of bacteria in patients with cirrhosis.
  4. Oral ofloxacin (400 mg twice per day) can be considered a substitute for intravenous cefotaxime in inpatients without prior exposure to quinolones, vomiting, shock, grade II (or higher) hepatic encephalopathy, or serum creatinine greater than 3 mg/dL.
  5. Patients with ascitic fluid PMN counts less than 250 cells/mm3 and signs or symptoms of infection (temperature >100ºF or abdominal pain or tenderness) should also receive empiric antibiotic therapy, e.g., intravenous cefotaxime 2 g every 8 hours, while awaiting results of cultures.
  6. When the ascitic fluid of a patient with cirrhosis is found to have a PMN count greater than or equal to 250 cells/mm3 and there is high suspicion of secondary peritonitis, it should also be tested for protein, lactic dehydrogenase, glucose, Gram’s stain, carcinoembryonic antigen, and alkaline phosphatase to assist with the distinction of SBP from secondary peritonitis. Computed tomographic scanning should also be performed.
  7. Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 in a nosocomial setting and/or in the presence of recent beta-lactam antibiotic exposure and/or culture an atypical organism(s) or have an atypical clinical response to treatment, should undergo a follow-up paracentesis after 48 hours of treatment to assess the response in PMN count and culture.
  8. Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 and clinical suspicion of SBP, who also have a serum creatinine >1 mg/dL, blood urea nitrogen >30 mg/dL, or total bilirubin >4 mg/dL should receive 1.5 g albumin per kg body weight within 6 hours of detection and 1.0 g/kg on day 3.

Followup Diagnostic Paracentesis

References

  1. Soares-Weiser K, Paul M, Brezis M, Leibovici L (2002). "Evidence based case report. Antibiotic treatment for spontaneous bacterial peritonitis". BMJ. 324 (7329): 100–2. PMC 1121993. PMID 11786457.
  2. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M; et al. (2014). "Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis". Gastroenterology. 146 (7): 1680–90.e1. doi:10.1053/j.gastro.2014.03.005. PMID 24631577.
  3. "AASLD Practice Guidelines: Management of Adult Patients with Ascites Due to Cirrhosis" (PDF).
  4. França A, Giordano HM, Sevá-Pereira T, Soares EC (2002). "Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients". J Gastroenterol. 37 (2): 119–22. PMID 11871762.
  5. 5.0 5.1 Terg R, Cobas S, Fassio E, Landeira G, Ríos B, Vasen W; et al. (2000). "Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study". J Hepatol. 33 (4): 564–9. PMID 11059861.
  6. Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A; et al. (1996). "Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis". Gastroenterology. 111 (4): 1011–7. PMID 8831596.
  7. Wiest R, Krag A, Gerbes A (2012). "Spontaneous bacterial peritonitis: recent guidelines and beyond". Gut. 61 (2): 297–310. doi:10.1136/gutjnl-2011-300779. PMID 22147550.
  8. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J (2010). "Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)". Antimicrob Agents Chemother. 54 (7): 3031–4. doi:10.1128/AAC.01808-09. PMC 2897303. PMID 20457818.
  9. 9.0 9.1 Runyon BA, AASLD (2013). "Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012". Hepatology. 57 (4): 1651–3. doi:10.1002/hep.26359. PMID 23463403.
  10. Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ (1982). "Spontaneous bacterial peritonitis". Hepatology. 2 (4): 399–407. PMID 7095741.
  11. European Association for the Study of the Liver (2010). "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis". J Hepatol. 53 (3): 397–417. doi:10.1016/j.jhep.2010.05.004. PMID 20633946.
  12. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D; et al. (2012). "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study". Hepatology. 55 (5): 1551–61. doi:10.1002/hep.25532. PMID 22183941.
  13. Navasa, M (1996-10). "Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis". Gastroenterology. 111 (4): 1011–1017. ISSN 0016-5085. PMID 8831596. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  14. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA (1991). "Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients". Gastroenterology. 100 (6): 1737–42. PMID 2019378.
  15. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N Engl J Med. 341 (6): 403–9. doi:10.1056/NEJM199908053410603. PMID 10432325.
  16. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M (2007). "Restricted use of albumin for spontaneous bacterial peritonitis". Gut. 56 (4): 597–9. doi:10.1136/gut.2006.113050. PMC 1856861. PMID 17369392.

Template:WS Template:WH